Detailed Mechanism Funding and Narrative

Years of mechanism: 2011 2012 2013 2014 2015 2016

Details for Mechanism ID: 13104
Country/Region: Uganda
Year: 2015
Main Partner: Baylor College of Medicine
Main Partner Program: Children's Foundation
Organizational Type: University
Funding Agency: HHS/CDC
Total Funding: $7,677,793 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $1,472,995
Care: Orphans and Vulnerable Children (HKID) $751,955
Care: TB/HIV (HVTB) $142,811
Care: Pediatric Care and Support (PDCS) $281,417
Laboratory Infrastructure (HLAB) $0
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $996,922
Testing: HIV Testing and Counseling (HVCT) $1,717,153
Sexual Prevention: Other Sexual Prevention (HVOP) $496,948
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $353,253
Treatment: Adult Treatment (HTXS) $1,409,014
Treatment: Pediatric Treatment (PDTX) $55,325
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2016 3,639
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2016 13,585
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2016 371
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2016 1,378
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2016 7,117
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2016 26,511
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2016 439
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2016 1,638
CARE_CURR Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 11,566
CARE_CURR Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 43,112
CARE_CURR Sum of Aggregated Age/Sex disaggregates 2016 11,566
CARE_CURR Sum of Aggregated Age/Sex disaggregates 2016 43,112
CARE_NEW Aggregated Age/sex: <15 Female 2016 299
CARE_NEW Aggregated Age/sex: <15 Male 2016 256
CARE_NEW Aggregated Age/sex: 15+ Female 2016 5,046
CARE_NEW Aggregated Age/sex: 15+ Male 2016 2,746
CARE_NEW Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 8,347
CARE_NEW Sum of Aggregated Age/sex disaggregates 2016 8,347
CARE_NEW Sum of Aggregated Age/sex disaggregates 2016 8,347
FN_THER Aggregated Age: <18 2016 403
FN_THER Aggregated Age: 18+ 2016 624
FN_THER Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period 2016 1,027
FN_THER Sum of Aggregated Age disaggregates 2016 1,027
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2016 21,969
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2016 16,572
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2016 25,132
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2016 167,112
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2016 253,608
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2016 120,524
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2016 182,883
HTS_TST By Test Result: Negative 2016 316,015
HTS_TST By Test Result: Negative 2016 479,216
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2016 326,177
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2016 494,944
HTS_TST Sum of Aggregated Age/Sex <15 2016 38,541
HTS_TST Sum of Aggregated Age/Sex <15 2016 58,453
HTS_TST Sum of Aggregated Age/Sex 15+ 2016 287,636
HTS_TST Sum of Aggregated Age/Sex 15+ 2016 436,491
HTS_TST Sum of Aggregated Age/Sex disaggregates 2016 326,177
HTS_TST Sum of Aggregated Age/Sex disaggregates 2016 494,944
HTS_TST Sum of Test Result disaggregates 2016 326,177
HTS_TST Sum of Test Result disaggregates 2016 494,944
HTS_TST_POS By Test Result: Positive 2016 10,162
HTS_TST_POS By Test Result: Positive 2016 15,728
LAB_CAP By clinical laboratories 2016 44
LAB_CAP Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests 2016 44
OVC_ACC Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services 2016 10,646
OVC_SERV Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2016 20,715
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2016 2,106
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2016 2,751
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2016 2,106
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2016 2,751
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2016 1,874
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2016 2,400
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2016 232
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2016 351
PMTCT_ARV Sum of New and Current disaggregates 2016 2,106
PMTCT_ARV Sum of New and Current disaggregates 2016 2,751
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2016 233
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2016 2,367
PMTCT_EID Sum of Infant Age disaggregates 2016 2,366
PMTCT_STAT By: Known positives at entry 2016 1,839
PMTCT_STAT By: Known positives at entry 2016 2,407
PMTCT_STAT By: Number of new positives identified 2016 267
PMTCT_STAT By: Number of new positives identified 2016 344
PMTCT_STAT Number of new ANC and L&D clients 2016 95,491
PMTCT_STAT Number of new ANC and L&D clients 2016 133,752
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2016 80,990
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2016 107,553
PMTCT_STAT Sum of Positives Status disaggregates 2016 2,106
PMTCT_STAT Sum of Positives Status disaggregates 2016 2,751
PP_PREV Age/sex: 10-14 Female 2016 17,324
PP_PREV Age/sex: 10-14 Male 2016 13,133
PP_PREV Age/sex: 15-19 Female 2016 40,952
PP_PREV Age/sex: 15-19 Male 2016 38,255
PP_PREV Age/sex: 20-24 Female 2016 60,775
PP_PREV Age/sex: 20-24 Male 2016 41,880
PP_PREV Age/sex: 25-49 Female 2016 87,079
PP_PREV Age/sex: 25-49 Male 2016 72,765
PP_PREV Age/sex: 50+ Female 2016 5,829
PP_PREV Age/sex: 50+ Male 2016 6,173
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2016 384,165
PP_PREV Sum of Age/Sex disaggregates 2016 384,165
TB_ART Aggregated Age: <15 2016 59
TB_ART Aggregated Age: 15+ 2016 714
TB_ART Female 2016 498
TB_ART Male 2016 275
TB_ART Sum of Aggregated Age disaggregates 2016 773
TB_ART Sum of Sex disaggregates 2016 773
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2016 969
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2016 773
TB_SCREEN Aggregated Age - USE WITH HQ PERMISSION ONLY: <15 2016 3,023
TB_SCREEN Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+ 2016 40,089
TB_SCREEN Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 11,566
TB_SCREEN Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 43,112
TB_SCREEN Sex: Female 2016 28,149
TB_SCREEN Sex: Male 2016 14,963
TB_SCREEN Sum of Aggregated Age disaggregates 2016 43,112
TB_SCREEN Sum of Sex disaggregates 2016 43,112
TB_SCREEN The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period 2016 43,112
TX_CURR Aggregated Age/Sex: 15+ Female 2016 3,143
TX_CURR Aggregated Age/Sex: 15+ Female 2016 11,958
TX_CURR Aggregated Age/Sex: 15+ Male 2016 6,829
TX_CURR Aggregated Age/Sex: 15+ Male 2016 25,976
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2016 10,765
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2016 40,949
TX_CURR Sum of Aggregated Age/Sex 15+ 2016 9,972
TX_CURR Sum of Aggregated Age/Sex 15+ 2016 37,934
TX_CURR Sum of Aggregated Age/Sex disaggregates 2016 9,972
TX_CURR Sum of Aggregated Age/Sex disaggregates 2016 37,934
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2016 3,211
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2016 6,779
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2016 10,432
TX_NEW Sum of Aggregated Age/Sex disaggregates 2016 9,990
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2016 11,280
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2016 13,269
VMMC_AE Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs) 2016 42
VMMC_CIRC By circumcision technique: Surgical VMMC 2016 13,000
VMMC_CIRC By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery 2016 13,000
VMMC_CIRC By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program) 2016 12,766
VMMC_CIRC By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site) 2016 234
VMMC_CIRC Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2016 13,000